Слезозаместительная терапия катионной эмульсией в комплексном лечении поверхностного точечного кератита у больных с гипотензивной терапией глаукомы
https://doi.org/10.21516/2072-0076-2016-9-4-52-57
Аннотация
Ключевые слова
Об авторах
С. В. ТруфановРоссия
С. А. Маложен
Россия
Д. А. Крахмалева
Россия
Е. А. Пивин
Россия
Список литературы
1. Marquis R.E., Whitson J.T. Management of glaucoma: focus on pharmacological therapy. Drugs and Aging. 2005; 22(1): 1-21.
2. Camras C.B., Toris C.B., Tamesis R.R. Efficacy and adverse effects of medications used in the treatment of glaucoma. Drugs and Aging, 1999; 15(5): 377-88.
3. Сафонова Т.Н., Федоров А.А., Забегайло А.О., Егорова Г.Б., Митичкина Т.С. Лечение синдрома «сухого глаза» при первичной глаукоме. Национальный журнал глаукома. 2015; 14 (4): 36-43.
4. De Saint Jean M., Debbasch C., Brignole F., et al. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000; 20: 85-94.
5. Burstein N.L. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol. 1980; 25: 15-30.
6. Burstein N.L. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc UK. 1985; 104: 402-9.
7. Егорова Г.Б., Федоров А.А., Митичкина Т.С., Шамсутдинова А.Р., Сафонова Т.Н. Влияние слезозаместительной и корнеопротекторной терапии на состояние глазной поверхности при синдроме «сухого глаза». Клиническая Офтальмология. 2015; 15(1): 15-21.
8. Wilcon L.A. To preserve or not to preserve, is that the question? Br. J. Ophthalmol. 1996; 80: 583-4.
9. Baudouin C., Labbé A., Liang H., Pauly A., Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog. Retin. Eye Res. 2010; 29: 312-34.
10. Fechtner R.D., Godfrey D.G., Budenz D., et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea 2010; 29: 618-21.
11. Friedman N.J. Impact of dry eye disease and treatment on quality of life. Current Opinion in Ophthalmology. 2010; 21(4): 310-6.
12. Noecker R.J., Herrygers L.A., Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004; 23: 490-6.
13. Becquet F., Goldschild M., Moldovan M.S., et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res. 1998; 17: 419-25.
14. Wilson F.M. Adverse external ocular effects of topical ophthalmic medications. Surv Ophthalmol. 1979; 24: 57-88.
15. Yalvac I.S., Gedikoglu G., Yaragöz Y., et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995; 73: 246-8.
16. Herreras J.M., Pastor J.C., Calonge M., et al. Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology. 1992; 99: 1082-8.
17. Burstein N.L. Preservative cytotoxic threshold for benzalkonium chloride and Chlorhexidine digluconate in cat and rabbit corneas. Invest. Ophthalmol. Vis Sci. 1980; 19: 308-13.
18. Grant R.L., Acosta D. Prolonged adverse effects of benzalkonium chloride and sodium dodecyl sulfate in a primary culture system of rabbit corneal epithelial cells. Fundam Appl Toxicol. 1996; 33: 71-82.
19. De Jong C., Solwijk T., Kuppens E., et al. Topical timolol with and without benzalkonium chloride; epithelial permeability and autofluorescence of the cornea in glaucoma. Graefes Arch. Clin. Exp. Ophthalmol. 1994; 232: 221-4.
20. Servat J.J., Bernardino C.R. Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging 2011; 28: 267-282.
21. Pisella P.J., Pouloquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol. 2002; 86: 418-23.
22. Bohn R.L., Gurwitz J.H., Yeomans S.M., et al. Which patients are treated for glaucoma? An observational analysis. J. Glaucoma. 2000; 9: 38-44.
23. Gordon J., Johnson P.J. Fibronectin Study Group-discontinuation of topical ophthalmic medications promotes healing of non-healing corneal epithelial defects. Invest. Ophthalmol. Vis Sci. 1991; 32:.1071.
24. Laflamme M.Y., Swieca R. A comparative study of two preservative-free tear substitutes in the management of severe dry eye. Can. J. Ophthalmol. 1988; 23: 174-6.
25. Miyata K., Amano S., Sawa M., Nishida T. A novel grading methods for superficial punctate keratopathy magnitude and its correlation with corneal epithelial permeability. Arch. Ophthalmol. 2003; 121(11): 1537-9.
26. Baudouin C., Renard J.-P.l, Nordmann J.-P., et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur. J. Ophthalmol. 2013; 23(1): 47-54.
27. Edelhauser H.F., Ubels J. The cornea and the sclera. In: Kaufman P.L., Alm A., eds. Adler’s Physiology of the Eye. 10th ed. St. Louis, MO: Mosby; 2003: 47-114.
Рецензия
Для цитирования:
Труфанов С.В., Маложен С.А., Крахмалева Д.А., Пивин Е.А. Слезозаместительная терапия катионной эмульсией в комплексном лечении поверхностного точечного кератита у больных с гипотензивной терапией глаукомы. Российский офтальмологический журнал. 2016;9(4):52-57. https://doi.org/10.21516/2072-0076-2016-9-4-52-57
For citation:
Trufanov S.V., Malozhen S.A., Krakhmaleva D.A., Pivin E.A. Tear replacement by cationic emulsion in complex therapy of superficial punctate keratitis in hypotensively medicated glaucoma patients. Russian Ophthalmological Journal. 2016;9(4):52-57. (In Russ.) https://doi.org/10.21516/2072-0076-2016-9-4-52-57